

**WYOMING MEDICAID
Preferred Drug List (PDL) June 8, 2026**

Drug classes not included on this list are not managed through a Preferred Drug List (PDL).
HOWEVER, THIS EXCLUSION IS NOT A GUARANTEE OF PAYMENT OR COVERAGE. Dosage limits and other requirements may apply.

Drugs new to market are non-preferred until a clinical review has been completed. PA criteria will apply to both the pediatric population,
as well as the adult population for those plans where PA/PDL limits are allowed.

Unless otherwise noted on the PDL, generic substitution is mandatory.

Yellow highlighted items below indicate new changes to the PDL. Red font indicates quantity/dosage limits apply. *Indicates BRAND is Preferred. May Use DAW 5.
Contact the OptumRx PA Helpdesk @ 877-207-1126 for prior authorization if client has primary insurance that will not cover the brand name medication.

Please refer to the Additional Therapeutic Criteria Chart, **Dosage Limitation List** (red font indicates quantity/dose limits apply), and Wyoming Medicaid Provider Manual for additional criteria.

THERAPEUTIC CLASS	PREFERRED AGENTS	PREFERRED AGENTS REQUIRING CLINICAL CRITERIA	CLINICAL CRITERIA	NON-PREFERRED AGENTS GENERIC MANDATORY POLICY APPLIES <small>THIS LIST IS NOT ALL-INCLUSIVE PLEASE CONTACT OptumRx WITH ANY QUESTIONS</small>		
ADDICTION	BUPRENORPHINE COMBINATIONS		<p>Client must have a diagnosis of opioid dependence or abuse. This is not to be used for the treatment of chronic pain. Prior authorization will be required before any narcotic, benzodiazepine, or carisoprodol prescription will be allowed between fills. Prior authorization will be required before any short-acting stimulant prescription from any doctor other than the prescriber of buprenorphine or Suboxone, will be allowed between fills.</p> <p>Oral buprenorphine will be approved for clients with a documented allergy to naloxone.</p> <p>Please submit PA requests on the "Oral Buprenorphine/Naloxone or Oral Buprenorphine" PA form available at www.wyomedical.org.</p> <p>Dosage limits apply Prior authorization will be required for doses >24mg</p>	<p>buprenorphine (oral) buprenorphine/naloxone film BRAND IS PREFERRED ZUBSOLV</p>		
	NALOXONE				<p>Kloxxado, naloxone products, and Narcan nasal spray will be limited to one fill per 180 days without prior authorization.</p> <p>Naloxone formulations available in quantities of 10ml will require prior authorization.</p>	<p>OPVEE REXTOVY</p>
	NALTREXONE					
	<p>VIVITROL</p> <p>naltrexone</p>					
ALLERGY / ASTHMA / COPD	ANTIHISTAMINES, MINIMALLY SEDATING		<p>Trial and failure of a preferred agent greater than or equal to a 14 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.</p>	<p>desloratadine levocetirizine</p>		
	<p>cetirizine fexofenadine loratadine</p>					
	ANTIHISTAMINE/DECONGESTANT COMBINATIONS		<p>Trial and failure of a preferred agent greater than or equal to a 14 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.</p>			
	<p>cetirizine/pseudoephedrine fexofenadine/pseudoephedrine loratadine/pseudoephedrine</p>					
	ANTICHOLINERGIC BRONCHODILATORS		<p>Trial and failure of a preferred agent greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent.</p> <p>Spiriva 5 day STARTER package will be allowed one (1) time per recipient.</p>	<p>TIOTROPIUM BROM (<i>use brand</i>) TUDORZA YUPELRI</p>		
	<p>ATROVENT HFA INCRUSE ELLIPTA ipratropium SPIRIVA HANDHALER* SPIRIVA RESPIMAT</p>					
	ANTICHOLINERGIC COMBINATION AGENTS		<p>Trial and failure of a preferred agent greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent.</p> <p>**Will also require the diagnosis of COPD.</p>	<p>BEVESPI DUAKLIR</p>		
	<p>ANORO ELLIPTA** BREZTRI COMBIVENT STIOLTO TRELEGY</p>					
	LEUKOTRIENE MODIFIERS		<p>Trial and failure of preferred agent greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent.</p>	<p>zafirlukast</p>		
	<p>montelukast</p>					
	LONG ACTING BRONCHODILATORS		<p>Trial and failure of two (2) preferred agents greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent.</p>	<p>BROVANA</p>		
	<p>arformoterol SEREVENT STRIVERDI</p>					
	NASAL ANTIHISTAMINES		<p>Trial and failure of preferred agent greater than or equal to 90 days in the last 12 months will be required before approval can be given for a non-preferred agent.</p>	<p>DYMISTA (<i>use separate agents</i>) olopatadine 0.6% RYALTRIS</p>		
	<p>azelastine 0.1%</p>					
	NASAL STEROIDS		<p>Trial and failure of two (2) preferred agents greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent.</p> <p>Budesonide will be approved for pregnancy.</p>	<p>DYMISTA (<i>use separate agents</i>) OMNARIS QNASL XHANCE</p>		
	<p>budesonide flunisolide fluticasone mometasone</p>					
	SHORT ACTING BRONCHODILATORS - INHALERS		<p>Trial and failure of a preferred agent greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent. Prior authorization will be required after a total of 12 albuterol inhalers are dispensed within 365 days.</p> <p>Minimum day supply of 16 days is required.</p>	<p>AIRSUPRA fevalbuterol (BRAND IS PREFERRED)</p>		
	<p>albuterol HFA PROAIR RESPICLICK VENTOLIN HFA XOPENEX HFA</p>					
	STEROID INHALANTS		<p>Trial and failure of two (2) preferred agents greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent.</p> <p>*Fluticasone HFA and Asmanex HFA will be approved for pediatric clients 8 years of age or younger.</p> <p>Alvesco will be approved for a history of oral thrush with steroid inhalants.</p>	<p>ALVESCO ASMANEX HFA* fluticasone HFA* QVAR REDIHALER</p>		
	<p>ARNUITY ELLIPTA ASMANEX TWISTHALER budesonide suspension</p>					
	STEROID COMBINATION AGENTS		<p>Trial and failure of a preferred agent greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent.</p> <p>**Will also require the diagnosis of COPD or uncontrolled asthma. Advair 7 and 14-day STARTER package will be allowed one (1) time per recipient.</p>	<p>BREYNA fluticasone/vilanterol (<i>use preferred agent</i>) fluticasone/salmeterol 55-14/113-14/232-14 fluticasone/salmeterol 100-50/250-50/500-50 (BRAND IS PREFERRED) WIXELA</p>		
	<p>ADVAIR (HFA, Diskus) BREQ ELLIPTA** DULERA SYMBICORT* TRELEGY</p>					
EPINEPHRINE		<p>Approval for these agents will require additional clinical criteria which can be found on the Additional Therapeutic Criteria Chart.</p>	<p>NEFFY</p>			
<p>AUVI-Q (<i>use preferred agent</i>) epinephrine auto-injector pen EPI-PEN</p>						
EOSINOPHILIC ASTHMA AGENTS			<p>FAENRA NUCALA TEZSPIRE</p>			
<p>DUPIXENT XOLAIR</p>						

**WYOMING MEDICAID
Preferred Drug List (PDL) June 8, 2026**

Please refer to the Additional Therapeutic Criteria Chart, Dosage Limitation List (red font indicates quantity/dose limits apply), and Wyoming Medicaid Provider Manual for additional criteria.				
THERAPEUTIC CLASS	PREFERRED AGENTS	PREFERRED AGENTS REQUIRING CLINICAL CRITERIA	CLINICAL CRITERIA	NON-PREFERRED AGENTS GENERIC MANDATORY POLICY APPLIES <small>THIS LIST IS NOT ALL INCLUSIVE PLEASE CONTACT OptumRx WITH ANY QUESTIONS</small>
DERMATOLOGY (continued)	ALOPECIA AREATA		Non-preferred agents require 90-day trial and failure of a high potency steroid as well as a documented SALT score of >50%.	LITFULO OLLUMIANT
	ATOPIC DERMATITIS		Dupixent requires member be at least 6 months of age or older; Adbry requires member be at least 12 years of age or older. No high-potency steroid trial will be necessary. For clients with >20% BSA, no immunomodulator trial and failure will be necessary for preferred agent(s).	ADBRY CIBINQO** NEMLUVIO OPZELURA**
	EBGLYSS DUPIXENT* RINVOQ ZORYVE		**Trial and failure of all criteria to receive a step 3 agent as defined above including medium/high potency topical corticosteroid, preferred step 2 immunomodulator AND 56-day trial and failure of a preferred biologic for Atopic Dermatitis in Step 3 will be required for approval of the non-preferred agents.	
	CHRONIC SPONTANEOUS URTICARIA		Client must have diagnosis of chronic spontaneous urticaria whose hives are not controlled by H1 antihistamine therapy.	RHAPSIDO
	DUPIXENT* XOLAIR		Approval for a non-preferred agent requires a 56-day trial and failure of a preferred agent.	
	PLAQUE PSORIASIS (PP)		Client must have diagnosis of PP prior to approval of a preferred agent. To receive a non-preferred agent, client must have a diagnosis of PP and a 56-day trial and failure of two of the preferred agents.	CIMZIA** COSENTYX ILUMYA REMICADE SKYRIZI STELARA TREMIFYA
	adalimumab-fkjp ENBREL HADLIMA HUMIRA OTEZLA SOTYKTU* TALTZ ZORYVE***		*Sotyktu requires diagnosis of moderate to severe PP and 56 day trial and failure of Humira. **Cimzia will be allowed for clients that are pregnant or breast-feeding ***Zoryve will be allowed for PP after a 21-day trial and failure of a high-potency corticosteroid OR a mild-potency corticosteroid if using in intertriginous areas.	
	SCABICIDES/PEDICULICIDES		Trial and failure of a preferred agent in the last 12 months.	NATROBA
	malathion lotion permethrin VANALICE			
	VITILIGO		Non-preferred agents require 90-day trial and failure of a medium or high potency steroid.	OPZELURA
DIABETES	DIABETES AGENTS			metformin SR 24H osm (use preferred agent) metformin SR 24H mod (use preferred agent)
	BIGUANIDES			
	metformin/ER			
	GLUCOSIDASE INHIBITORS		Trial and failure of metformin and a preferred agent greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	miglitol
	acarbose			
	MEGLITINIDES		Trial and failure of metformin and a preferred agent greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	repaglinide
	nateglinide			
	THIAZOLIDINEDIONES		Trial and failure of metformin and a preferred agent greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	ACTOPLUS MET (use separate agents)
	pioglitazone			
	SULFONYLUREAS		Trial and failure of metformin and a preferred agent greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	
	glimperide/ER glipizide/ER glyburide/ER			
	DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS		Trial and failure of metformin greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a preferred agent. A 90 day trial and failure of the preferred agent is required before approval can be given for a non-preferred agent.	alogliptin GLYXAMBI (use separate preferred agents) STEGLIJUAN (use separate preferred agents)
	JANUVIA ONGLYZA TRADJENTA			
	DPP-4 INHIBITOR COMBO AGENTS		Trial and failure of metformin greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a preferred agent. A 90 day trial of failure of the preferred agent is required before approval can be given for a non-preferred agent.	alogliptin/metformin alogliptin/pioglitazone (use separate preferred agents) JENTADUETO XR saxagliptin/metformin (BRAND IS PREFERRED) sitagliptin/metformin (BRAND IS PREFERRED)
	JANUMET/XR JENTADUETO			
	INCRETIN MIMETICS (GLP-1 RECEPTOR AGONISTS)		Trial and failure of metformin greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a preferred agent unless ASCVD or risk factors are present, in which case the trial of metformin is waived. A 90 day trial of failure of the preferred agent is required before approval can be given for a non-preferred agent.	liraglutide (use brand) MOUNJARO OZEMPIC* SOLIQUA XULTOPHY (use separate preferred agents)
	exenatide OZEMPIC (tablets) RYBELSUS TRULICITY VICIENZA*		Dosage Limits Apply: Ozempic: 2mg/week Victoza: 1.8mg/day	
	SGLT2 INHIBITORS		Trial and failure of metformin greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a preferred agent unless there is a diagnosis of ASCVD, CKD, or heart failure, in which case the trial of metformin will be waived. A 90 day trial and failure of a preferred agent is required before approval can be given for a non-preferred agent.	GLYXAMBI (use separate preferred agents) INVOKAMET INVOKANA SEGLUROMET (use separate preferred agents) STEGLATRO STEGLIJUAN (use separate preferred agents) SYNJARDO XR (use separate preferred agents) TRILIARDY XR (use separate preferred agents)
	FARXIGA JARDIANCE SYNJARDO XIGDUO XR			
	FAST-ACTING INSULIN		Prior authorization will be required when using two different delivery forms of the same type of insulin concurrently.	ADMELOG (use preferred agent) FIASP (use preferred agent) insulin lispro (use preferred agents) LYUMJEV
	HUMALOG HUMALOG 75/25 HUMALOG JR. HUMALOG MIX NOVOLOG MIX			
	LONG-ACTING INSULIN		Prior authorization will be required when using two different delivery forms of the same type of insulin concurrently.	BASAGLAR (use preferred agent) Insulin Glargine (use preferred agent) Insulin Degludec SOLIQUA TOUJEO (use preferred agent) TRESIBA* (use preferred agent) XULTOPHY (use separate preferred agents)
	LANTUS SOLOSTAR* LANTUS vial			
	DIABETIC METERS/TEST STRIPS		Quantity limits apply: Insulin Dependent Clients: 10 strips/day Non-Insulin Dependent Clients: 4 strips/day Clients are limited to 1 meter/365 days	ALL OTHER METERS AND TEST STRIPS ONE TOUCH ULTRA II ONE TOUCH ULTRA MINI ONE TOUCH ULTRA BLUE ONE TOUCH VERIO ONE TOUCH VERIO FLEX ONE TOUCH VERIO REFLECT ONE TOUCH VERIO IQ
	ACCU-CHEK GUIDE/STRIPS ACCU-CHEK GUIDE ME FREESTYLE (strips only) FREESTYLE FREEDOM FREESTYLE FREEDOM LITE FREESTYLE INSULINX FREESTYLE PRECISION NEO B FREESTYLE SIDEKICK II PRECISION XTRA			
	EXTERNAL DIABETIC DEVICES			OMNIPOD GO
	OMNIPOD DASH OMNIPOD 5 OMNIPOD G5 FSL 2 PLUS G6			
CONTINUOUS BLOOD GLUCOSE MONITORS		Prior authorization will be required to verify if the client is injecting insulin daily. Monitors will also be limited to the labeled age. CGMs will be approved for gestational diabetes through 6-week post partum checkup.	GUARDIAN MINIMED	
DEXCOM G6 DEXCOM G7 FREESTYLE LIBRE FREESTYLE LIBRE 2 FREESTYLE LIBRE 3/PLUS				

**WYOMING MEDICAID
Preferred Drug List (PDL) June 8, 2026**

Please refer to the Additional Therapeutic Criteria Chart, **Dosage Limitation List (red font indicates quantity/dose limits apply)**, and Wyoming Medicaid Provider Manual for additional criteria.

THERAPEUTIC CLASS	PREFERRED AGENTS	PREFERRED AGENTS REQUIRING CLINICAL CRITERIA	CLINICAL CRITERIA	NON-PREFERRED AGENTS GENERIC MANDATORY POLICY APPLIES <small>THIS LIST IS NOT ALL INCLUSIVE PLEASE CONTACT OptumRx WITH ANY QUESTIONS</small>
DIABETES (continued)	ACUTE HYPOGLYCEMIA AGENTS			GVOKE (use preferred agent)
	BAOSIMI ZEGALOGUE (autoinjector)			
FIBROMYALGIA	FIBROMYALGIA		Trial and failure of a preferred agent greater than or equal to six (6) weeks in the last 12 months is required prior to approval of a non-preferred agent Clients will not be allowed to take gabapentin and pregabalin concurrently	pregabalin SAVELLA tablets (savella titration pak will not be covered)
	amitriptyline cyclobenzaprine duloxetine	gabapentin		
GASTROINTESTINAL	BOWEL EVACUANTS			SUTAB
	CLENPIQ GAVILYTE G, N PEG 3350 SOLUTION SUFLAVE SUPREP			
	CHRONIC IDIOPATHIC CONSTIPATION		Client must have a diagnosis of chronic idiopathic constipation to receive a preferred agent. To receive a non-preferred agent, the client must have a diagnosis of chronic idiopathic constipation and a 30-day trial and failure of a preferred agent within the last 12 months.	MOTEGRITY
		LINZESS lubiprostone		
	DIGESTIVE ENZYMES		Prior authorization required.	VIOKACE
	CREON ZENPEP	PERTZYE*	*Pertzye will be preferred for members diagnosed with cystic fibrosis.	
	IRRITABLE BOWEL SYNDROME WITH CONSTIPATION		Client must have a diagnosis of Irritable Bowel Syndrome (IBS) with constipation.	
		LINZESS lubiprostone		
	MESALAMINE		Trial and failure of a preferred agent greater than or equal to a 14 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	mesalamine DR tab 800mg, 1.2g mesalamine ER cap 0.375gm mesalamine sup 1000mg SFLOWASA
	LIALDA* mesalamine 400mg DR capsule mesalamine enema PENTASA			
	OPIOID-INDUCED CONSTIPATION AGENTS		Client must have a diagnosis of opioid-induced constipation and a three (3) month trial and failure of a stool softener to receive the preferred agent. To receive the non-preferred agent, the client must have a diagnosis of opioid-induced constipation, a three (3) month trial and failure of a secretory agent, and a three (3) month trial and failure of the preferred agent. *Movantik and Symproic will be approved for a diagnosis of cancer or for clients in hospice or palliative care.	MOVANTIK* SYMPROIC*
		lubiprostone		
	PREGNANCY INDUCED NAUSEA/VOMITING			BONJESTA DICLEGIS
		doxylamine/pyridoxine		
	PROTON PUMP INHIBITORS		Trial and failure of a preferred agent greater than or equal to a 14 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	amox/clarith/anso pack DEXILANT dexlansoprazole esomeprazole omeprazole 20.6mg capsules omeprazole tablets omeprazole/sodium bicarbonate PREVACID solutabs (use preferred agents) rabeprazole TALICIA (use separate agents)
lansoprazole capsules/ODT omeprazole capsules/ODT pantoprazole				
POTASSIUM COMPETITIVE ACID REDUCERS		Voquezna will require trial and failure of two proton pump inhibitors twice daily at max dose for 30 days	VOQUEZNA	
GOUT	COLCHICINE			MITTIGARE (use preferred agent)
	colchicine (tablets)			
	XANTHINE OXIDASE AND URATI INHIBITORS		Trial and failure of the preferred agent greater than or equal to a 60 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	ULORIC*
allopurinol				
HEMATOLOGY	LOW MOLECULAR WEIGHT HEPARIN (LMWH)		Prior authorization will be required for the 300mg/3ml strength.	FRAGMIN (use preferred agent) enoxaparin 300MG/3ML
	enoxaparin			
	DIRECT THROMBIN INHIBITOR		Client must have diagnosis of non-valvular atrial fibrillation and relative contraindication to warfarin for approval, treatment for deep vein thrombosis (DVT) or pulmonary embolism (PE), or for the reduction in the risk of recurrence of DVT and PE after initial therapy.	
		PRADAXA		
	SELECTIVE FACTOR XA INHIBITOR		*To receive Xarelto 2.5mg, client must have a diagnosis of chronic coronary artery disease or peripheral artery disease with the need to reduce risk of major cardiovascular events	SAVAYSA (use preferred agent)
	ELIQUIS (tablets or starter pak) XARELTO (10/15/20mg, starter)	XARELTO 2.5mg*		
	CPTP DERIVATIVES		Client must have a diagnosis of acute coronary syndrome, history of myocardial infarction, or history of stroke and transient ischemic attack.	
		BRILINTA		
	ANTIHEMOPHILIC FACTOR VIII			ALTUVIIIO KOVALTRY
	ADVATE ADYNOVATE AFSTYLA ELOCTATE ESPEROCT HEMOFIL M HEMLIBRA JIVI KOATE/KOATE-DVI NOVOEIGHT NUWIQ OBIZUR RECOMBINATE XYNTHA/SOLOFUSE			
	COAGULATION FACTOR IX			
	ALHEMO ALPHANINE SD ALPROLIX BENEFIX IDELVION IXINITY REBINYN RIXUBIS			
	ANTIHEMOPHILIC FACTOR/VWF			
	ALPHANATE HUMATE-P VONVENDI WILATE			
	ERYTHROPOIESIS STIMULATING AGENTS			ARANESP MIRCERA PROCRIT
EPOGEN RETACRIT				
ADDITIONAL HEMATOLOGICAL AGENTS		*Requires Sickle Cell Disease diagnosis **Additional criteria and diagnosis of beta-thalassemia required.		
SIKLOS*	ZYNTLEGRO**			

**WYOMING MEDICAID
Preferred Drug List (PDL) June 8, 2026**

Please refer to the Additional Therapeutic Criteria Chart, Dosage Limitation List (red font indicates quantity/dose limits apply), and Wyoming Medicaid Provider Manual for additional criteria.					
THERAPEUTIC CLASS	PREFERRED AGENTS	PREFERRED AGENTS REQUIRING CLINICAL CRITERIA	CLINICAL CRITERIA	NON-PREFERRED AGENTS GENERIC MANDATORY POLICY APPLIES <small>OTHER OFFERS MAY ALSO BE AVAILABLE PLEASE CONTACT OHSUMS WITH ANY QUESTIONS</small>	
HEPATITIS C		DIRECT ACTING ANTIVIRALS sofosbuvir/velbatavir MAVYRET	Limited to FDA approved indication. Prior authorization will be required prior to use of preferred agents. Please submit PA requests on the Hepatitis C PA form available at www.wymedicaid.org .	EPCLUSA (use preferred agent) HARVONI SOVALDI VOSEVI ZEPATIER	
HIDRADENITIS SUPPURATIVA		IMMUNOMODULATORS HUMIRA	Humira will not be covered as a first line agent for the diagnosis for hidradenitis suppurativa.	COSENTYX	
HORMONES		GnRH ANTAGONISTS MYFEMBREE ORIAHN ORILISSA	*Please refer to the Additional Therapeutic Criteria chart at www.wymedicaid.org for specific requirements.		
		GROWTH HORMONE GENOTROPIN NORDITROPIN SKYTROFA		HUMATROPE NGENLA SEROSTIM SOGROYA ZOMACTON	
		TESTOSTERONE TOPICAL GELS TESTIM GEL	Testosterone agents are only allowed for diagnosis of hypogonadism or insufficient testosterone production. <i>Other testosterone dosage form products will require a diagnosis of hypogonadism or insufficient testosterone production (not outlined on PDL).</i>	JATENZO (use preferred agent) TESTOPEL (use preferred agent) testosterone gel (use preferred agent) testosterone solution (use preferred agent) XYOSTED (use preferred agent)	
		THYROID HORMONES ARMOUR THYROID LEVOXYL levothyroxine (tablets) LEVO-T liothyronine SYNTHROID UNITHROID		Ermeza will be covered with confirmed diagnosis of dysphagia.	THYQUIDITY
		CONTRACEPTIVES altavera amethyst apri ashlyna apri ashlyna aurovela 1-20/FE 1-20, 1-35 aviane ayuna azurette bilsovi 1-20 FE, 1.5-30 FE beyaz camila camrese/LO chateal/EQ CHARLOTTE 24 FE chew cyred dasetta 1-35, 7/7/7 daysee deblitane deso/ethinyl estradiol drospir/ethinyl estradiol elinest emzahn enskyce errin estarylla falmina finzala FE chew hailey FE 1/20, 1/35 heather iclevia incassia introvale isibloom jaimiess jencycla jolesa juleber junel 1-20/FE, 1.5-30/FE kalliga kariva kelnor kurvelo larin 1-20/FE, 1.5-30/FE lessina levora lo loestrin loestrin FE loryna low-ogestrel luteru marlissa mibelas FE chew microgestin 1-20/FE, 1.5-30/FE mili mono-lynyah natazia NECON 0.5/35 nikki nora-be noreth/ethinyl estradiol/FE chw noreth/ethinyl estradiol 1-20/FE norgest/ethinyl estradiol/LO norethindrone nylia pimtrea portia reclipsen setlakin sharobel simliya simpesse			alyacen 1-35, 7/7/7 aranelle BALCOLTRA balziva briellyn drospir/ethinyl estradiol/levomefolate enpresse FEMLYV kailib FE chew levonest levonorgest/ethinyl estradiol/LO (84-7) levonorgest/ethinyl estradiol 0.15- NEXTSTELLIS noreth/ethinyl estradiol/FE chew 0.8/25 nortrel OPILL philit rivelsa SAFYRAL SLYND TAYSOFY TAYTULLA tilia FE tri-legest FE TWIRLA TYBLUME tydemy vyfemia wera wymzya FE chew

**WYOMING MEDICAID
Preferred Drug List (PDL) June 8, 2026**

Please refer to the Additional Therapeutic Criteria Chart, [Dosage Limitation List](#) (red font indicates quantity/dose limits apply), and Wyoming Medicaid Provider Manual for additional criteria.

THERAPEUTIC CLASS	PREFERRED AGENTS	PREFERRED AGENTS REQUIRING CLINICAL CRITERIA	CLINICAL CRITERIA	NON-PREFERRED AGENTS GENERIC MANDATORY POLICY APPLIES <small>THIS LIST IS NOT ALL INCLUSIVE PLEASE CONTACT Opioids WITH ANY QUESTIONS</small>
HORMONES; CONTRACEPTIVES <i>(continued)</i>	sprintec sronyx syeda tri-estarylla/LO tri-linyah tri-marzia LO tri-mili/LO tri-sprintec/LO tri-vylibra velivet vestura vienva viorele volnea vylibra yasmin-28 XULANE YAZ ZAFEMY zumandimine			
HYPERLIPIDEMIA	BILE ACID SEQUESTRANT		Trial and failure of ALL preferred agents greater than or equal to six (6) months in the last 12 months will be required before approval can be given for a non- preferred agent.	WELCHOL
	STATINS, LOW POTENCY		Trial and failure of a preferred agent greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a non-preferred agent. If client's current medication therapy is contraindicated with the preferred statin(s) due to a drug-drug interaction, a non-preferred agent may be obtained with a prior authorization. Prior authorization will be required for clients under the age of 10.	fluvastatin/ER
	STATINS, HIGH POTENCY		Trial and failure of a preferred agent greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a non-preferred agent. If client's current medication therapy is contraindicated with the preferred statin(s) due to a drug-drug interaction, a non-preferred agent may be obtained with a prior authorization. Prior authorization will be required for clients under the age of 10.	LUVALO ZYPITAMAG
	STATIN COMBINATIONS		Trial and failure of a preferred agent greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a non-preferred agent. Prior authorization will be required for clients under the age of 10.	ezetimibe/simvastatin (BRAND IS PREFERRED)
	PCSK9-RELATED AGENTS		Client must have a diagnosis of homozygous familial hypercholesterolemia; have a diagnosis of heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease AND not at goal with a maximum dose statin; or be intolerant to statin therapy. Approval for a non-preferred agent requires trial and failure of a preferred agent.	LERECHOL LEQVIO
	TRIGLYCERIDE LOWERING AGENTS		Trial and failure of a preferred agent greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	fenofibric acid fenofibrate (43/50/120/130/150mg) icosapent LIPOFEN
	ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)		Non-preferred ARBs will require a history of ALL preferred ARBs before approval	candesartan
	ARBs AND DIURETICS		Non-preferred ARB/diuretic combinations will require a history of ALL preferred	candesartan HCTZ telmisartan HCTZ
HYPERTENSION/ CARDIOLOGY	ALPHA-BLOCKERS			
	COMBINATION PRODUCTS		Client must be greater than one year of age and have a diagnosis of Congestive Heart Failure (CHF) NYHA Class II-IV. Angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) will not be allowed in combination with Entresto.	ENTRESTO SPRINKLES VERQUVO
	ANTI-VIRALS		Paxlovid requires COVID diagnosis. Product is limited to 1 dosepak per 30 days.	
	QUINOLONES			moxifloxacin (<i>use preferred agents</i>)
INFECTIOUS DISEASE	DOXYCYCLINE			DORYX (<i>use preferred agent</i>)
	MINOCYCLINE			minocycline 65mg and 115mg ER (<i>use preferred agent</i>)
	INHALED TOBRAMYCIN		*Tobi Podhaler requires a 28 day trial of a preferred agent, as well as 28 days off of that same preferred agent prior to approval. Minimum day supply of 56 days is required	BETHKIS inhaled tobramycin TOBI PODHALER (<i>use preferred agent</i>)

**WYOMING MEDICAID
Preferred Drug List (PDL) June 8, 2026**

Please refer to the Additional Therapeutic Criteria Chart, [Dosage Limitation List](#) (red font indicates quantity/dose limits apply), and Wyoming Medicaid Provider Manual for additional criteria.

THERAPEUTIC CLASS	PREFERRED AGENTS	PREFERRED AGENTS REQUIRING CLINICAL CRITERIA	CLINICAL CRITERIA	NON-PREFERRED AGENTS GENERIC MANDATORY POLICY APPLIES <small>OTHER AGENTS MAY ALSO BE INCLUDED PLEASE CONTACT ODHSMR WITH ANY QUESTIONS</small>
INFECTIOUS DISEASE (continued)	ANTI-RETROVIRALS		*Please refer to the Additional Therapeutic Criteria chart at www.wyomedicaid.org for specific requirements. **Rukobia approval requires documentation of multi-drug resistance defined as failure of two medications from different classes.	CABENUVA EMCITRABINE/RILPIVIRINE/TENOFOVIR JULUCA NORVIR RUKOBIA** STRIBILD (use separate agents) SUNLENCA SYM TUZA (use separate preferred agents)
	APRETUDE BIKTARVY CINDUO COMPLERA DELSTRIGO DOVATO EVOTAZ GENVOYA ODEFSEY PIFELTRO PREZCOBIX ritonavir tablets TRIUMEQ TROGARZO	DESCOVY* TRUVADA*		
INFLAMMATION	NSAIDs		Trial and failure of two (2) preferred agents each greater than or equal to a 14 day supply in the last 12 months will be required before approval can be given for a non- preferred agent. Dosing and quantity limits apply for ketorolac (limit 5days/34 days; max dose 40mg/day for oral tablets). *Diclofenac 3% requires diagnosis of actinic keratosis	CALDOLOR (use preferred agent) diclofenac 1.3% patch diclofenac 1.5% soln. diclofenac 3% gel* fenoprofen mefenamic acid NEOPROFEN (use preferred agent)
	celecoxib diclofenac tablets etodolac flurbiprofen ibuprofen indomethacin ketoprofen ketorolac meclufenamate meloxicam nabumetone naproxen oxaprozin piroxicam sulindac			
	ORAL CORTICOSTEROIDS			CELESTONE (use preferred agent) EMFLAZA
INSOMNIA	NON-BENZODIAZEPINES		Trial and failure of a preferred agent greater than or equal to a 14 day supply in the last 12 months will be required before approval can be given for a non-preferred agent. Prior Authorization will be required for clients under the age of 18 *Quiviviq requires trial and failure of two preferred agents with different mechanisms of action **Rozerem is non-preferred unless member has history of substance abuse Prior authorization will be required when a client is taking more than one insomnia agent concurrently. Dosage limits apply; zaleplon: 30mg/day zolpidem: 10mg/day	EDLUAR (additional criteria applies) DAYVIGO QUUVIVIQ* ROZEREM** zolpidem sublingual (additional criteria applies)
	BELSOMRA eszopiclone zaleplon zolpidem zolpidem ER			
MASH (Metabolic-Associated Steatohepatitis)	APPROVED AGENTS		*Wegovy injectables will require diagnosis of MASH. Please consult the Additional Therapeutics Clinical Criteria chart for more information regarding cardiovascular disease criteria.	REZDIFRA
		WEGOVY (INJECTABLE)* WEGOVY HD (INJECTABLE)*		
MENTAL HEALTH	ALZHEIMER'S AGENTS		Client must have a diagnosis of dementia.	donepezil 23mg (use preferred agent) memantine ER NAMZARIC (use separate agents) rivastigmine capsules/patches
		donepezil/ODT galantamine/ER memantine tablets/solution		
	ANTIDEPRESSANTS		Trial and failure of two (2) preferred agents greater than or equal to six (6) weeks WITHIN THE LAST 2 YEARS will be required before approval can be given for a non-preferred agent. One of the trials of preferred agents must be in the same class (NaSS, NDRI, SSRI, or SNRI) as the requested non-preferred agent.	
	NORADRENERGIC/SPECIFIC SEROTONERGICS (NaSS)			NaSS
	mirtazapine tablets			mirtazapine rapid dissolve tablets (use preferred agent)
	NOREPINEPHRINE/DOPAMINE REUPTAKE INHIBITORS (NDRI)			NDRI
	bupropion ER/SR/XL			AUVELITY
	SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRI)		Trazodone, bupropion, fluvoxamine, MAO inhibitors, TCA's, bupropion IR, and venlafaxine IR do not require prior authorization but will not count towards meeting preferred therapy requirements.	SSRI
	citalopram escitalopram fluoxetine capsules paroxetine IR/CR sertraline			BUCAPSOL citalopram capsules fluoxetine tablets VIIBRYD
	SEROTONIN/NOREPINEPHRINE REUPTAKE INHIBITORS (SNRI)		Clients will not be allowed to be on more than one antidepressant, including fluvoxamine, bupropion IR, and venlafaxine IR, at one time with the exception of mirtazapine or bupropion with a SSRI or SNRI. ***Trintellix requires trial and failure of two preferred agents in any class	SNRI
duloxetine venlafaxine ER capsules		Clients five (5) years of age and younger will require prior authorization before approval. Dosage limits apply: bupropion ER/SR/XL: 450mg/day citalopram < 60 years of age: 60mg/day citalopram > 60 years of age: 30mg/day escitalopram: 30mg/day fluoxetine < 18 years of age: 90mg/day fluoxetine > 18 years of age: 120mg/day mirtazapine: 67.5mg/day paroxetine IR/CR < 18 years of age: 75mg/day paroxetine IR > 18 years of age: 90mg/day paroxetine CR > 18 years of age: 112.5mg/day sertraline: 300mg/day venlafaxine ER: 337.5mg/day	desvenlafaxine FETZIMA venlafaxine ER tablets (use preferred agent)	
			OTHER TRINTELLIX***	

**WYOMING MEDICAID
Preferred Drug List (PDL) June 8, 2026**

Please refer to the Additional Therapeutic Criteria Chart, [Dosage Limitation List](#) (red font indicates quantity/dose limits apply), and Wyoming Medicaid Provider Manual for additional criteria.

THERAPEUTIC CLASS	PREFERRED AGENTS	PREFERRED AGENTS REQUIRING CLINICAL CRITERIA	CLINICAL CRITERIA	NON-PREFERRED AGENTS GENERIC MANDATORY POLICY APPLIES <small>THIS LIST IS NOT ALL INCLUSIVE PLEASE CONTACT OptumRx WITH ANY QUESTIONS</small>
MENTAL HEALTH (continued)	ATYPICAL ANTIPSYCHOTICS		<p>*Quetiapine doses less than 100mg will require prior authorization <u>without</u> a diagnosis of mood disorder or major depressive disorder. For titration doses, contact the OptumRx Pharmacy Help Desk for an override.</p> <p>**Clients nine (9) years of age and younger will require a prior authorization to receive approval of lurasidone and asenapine. Clients eighteen (18) years of age and younger will require a prior authorization to receive approval of Fanapt.</p> <p>***Rexulti or Caplyta approval for MDD treatment requires concurrent antidepressant therapy as well as a trial and failure of aripiprazole or other preferred atypical antipsychotic indicated for adjunct MDD treatment.</p> <p>Trial and failure of two (2) preferred agents greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent unless otherwise specified.</p> <p>Prior authorization will be required for any client five (5) years of age or younger, or for any client taking both an injectable and oral dosage form of the same medication concurrently.</p> <p>Dosage limits apply: aripiprazole <13 years of age: 15mg/day; ≥13 years of age: 30mg/day asenapine: 20mg/day ABILIFY MAINTENA: 400mg per 26 days ARISTADA 441/662/882mg: 1 injection per 28 days; 1064mg: 1 injection per 56 days ARISTADA INITIO: 1 injection per 365 days FANAPT: 24mg/day INVEGA HAFYERA: 1 injection per 6 months INVEGA SUSTENNA: 1 injection per 28 days INVEGA TRINZA: 1 injection per 84 days lurasidone 10-17 years of age: 80mg/day; >17 years of age: 160mg/day olanzapine <13 years of age: 10mg/day; ≥13 years of age: 20mg/day paliperidone: 12mg/day PERSERIS: 1 injection per 28 days quetiapine <13 years of age: 400mg/day; 13-17 years of age: 600mg/day; >17 years of age: 800mg/day risperidone <10 years of age: 3mg/day; 10-17 years of age: 6mg/day; >17 years of age: 16mg/day RISPERDAL CONSTA: 2 injections per 28 days ziprasidone ≤17 years of age: 120mg/day; >17 years of age: 200mg/day</p>	<p>ABILIFY MYCITE (<i>use preferred agent</i>) CAPLYTA*** COBENFY GEODON 20MG INJ LYBALVI (<i>additional criteria applies</i>) NUPLAZID olanzapine 10mg Inj SAPHRIS (<i>use preferred agent</i>) SECUADO REXULTI*** RYKINDO ZYPREXA RELPREVV</p>
	SPECIAL ATYPICAL ANTIPSYCHOTICS		Dosage limits apply: 900mg/day	VERSACLOZ Suspension (<i>use preferred agent</i>)
	clozapine/ODT			
	AMPHETAMINES			AMPHETAMINES
	LONG ACTING AMPHETAMINES		<p>ADDERALL XR* amphetamine salts combo XR dextroamphetamine CR caps VYVANSE CAPSULES**</p>	<p>ADZENYS XR ODT DYANAVAL XR MYDAYIS PROCENTRA VYVANSE CHEWABLES ZENZEDI</p>
	IMMEDIATE RELEASE AMPHETAMINES		<p>amphetamine salts combo dextroamphetamine tablets</p>	
	METHYLPHENIDATES			METHYLPHENIDATES
	LONG ACTING METHYLPHENIDATES		<p>CONCERTA* dexamethylphenidate ER methylphenidate ER tablets</p>	<p>APTENSIO XR AZSTARYS COTEMPLA XR DAYTRANA FOCALIN XR JORNAY PM methylphenidate ER osmotic release (BRAND IS PREFERRED) methylphenidate ER/CR/SR capsules (RITALIN LA, APTENSIO XR) RELEXII QUILLICHEW ER QUILLIVANT</p>
	IMMEDIATE RELEASE METHYLPHENIDATES		<p>dexamethylphenidate methylphenidate chewables methylphenidate solution methylphenidate tablets</p>	
				<p>For clients over the age of 17, they must meet the DSM-5 criteria for diagnosis of ADHD. These criteria include:</p> <ul style="list-style-type: none"> • Five or more symptoms of inattention, present for at least 6 months, inappropriate for developmental level. OR • Five or more symptoms of hyperactivity and impulsivity, present for at least 6 months, to an extent that is disruptive and inappropriate for developmental level. AND • Symptoms must be present in two or more settings (home, school or work); • There must be clear evidence that the symptoms interfere or reduce the quality of social, school or work functioning; and • The symptoms must not be better explained by another mental disorder. <p>Diagnosis of MS fatigue will require a fatigue severity scale score of 5.0, a 60-day trial of amantadine and discontinuation of medications that may contribute to drowsiness and fatigue.</p> <p>Diagnosis of refractory depression will require a 6-week trial and failure of an antidepressant (monotherapy) and continued concomitant use of an antidepressant with the stimulant.</p> <p>**Vyvanse will be approved for the diagnosis of binge-eating disorder for clients 18 years of age and older. Authorizations will be approved for 12 weeks. After initiation a one-year prior authorization of Vyvanse for this diagnosis will require additional documentation prior to approval.</p> <p>Claims will require Prior Authorization if client is under the age of 4, or has a history of the following: glaucoma, cardiac arrhythmias, arteriosclerosis, untreated hypertension, untreated hyperthyroidism, substance abuse, or current MAO inhibitor use.</p> <p>Trial and failure of two (2) preferred agents (each from a different class: methylphenidate and amphetamine) greater than or equal to a 30 day supply in the last 12 months will be required before approval can be given for a non-preferred agent. Two or more long-acting agents will not be allowed concurrently.</p> <p>Dosage limits apply: amphetamine salts combo XR: 60mg/day amphetamine salts combo: 60mg/day amphetamine salts combo (narcolepsy): 90mg/day DAYTRANA: 45mg/9 hour patch/day dextroamphetamine: 90mg/day dextroamphetamine CR: 90mg/day dexamethylphenidate: 30mg/day FOCALIN XR < 13 years of age: 45mg/day FOCALIN XR > 13 years of age: 60mg/day JORNAY PM: 100mg/day methylin/methylphenidate/ER: 90mg/day VYVANSE: 70mg/day</p>

**WYOMING MEDICAID
Preferred Drug List (PDL) June 8, 2026**

Please refer to the Additional Therapeutic Criteria Chart, [Dosage Limitation List](#) (red font indicates quantity/dose limits apply), and Wyoming Medicaid Provider Manual for additional criteria.

THERAPEUTIC CLASS	PREFERRED AGENTS	PREFERRED AGENTS REQUIRING CLINICAL CRITERIA	CLINICAL CRITERIA	NON-PREFERRED AGENTS GENERIC MANDATORY POLICY APPLIES <small>THIS LIST IS NOT ALL INCLUSIVE PLEASE CONTACT ODHSMR WITH ANY QUESTIONS</small>
MENTAL HEALTH continued	SELECTIVE ALPHA-ADRENERGIC AGONIST		Client must have a diagnosis of ADD or ADHD. Prior authorization will be required for clients under the age of 4.	ONYDA XR
	clonidine, clonidine ER guanfacine, guanfacine ER			
	SELECTIVE NOREPINEPHRINE REUPTAKE INHIBITOR		Atomoxetine: Clients must have a diagnosis for ADD, ADHD, narcolepsy, obstructive sleep apnea, shift work sleep disturbance, or refractory depression (see refractory depression criteria below). Diagnosis of refractory depression will require a 6-week trial and failure of an antidepressant (monotherapy) and continued concomitant use of an antidepressant with the stimulant. Prior Authorization required for clients under the age of 4. Claims will require Prior Authorization if clients have a history of the following: glaucoma, cardiac arrhythmias, arteriosclerosis, untreated hypertension, untreated hyperthyroidism, substance abuse, or current MAO inhibitor use. Qelbree: Clients must have a 30-day trial and failure of a preferred non-stimulant OR trial and failure of two preferred ADHD agents. Approval will be limited to a max dose of 400mg in clients 6-17 years of age, and 600mg for clients 18 years of age or older. Dosage limits apply: atomoxetine: 100mg/day	
		atomoxetine QELBREE		
MIGRAINE	MIGRAINE PROPHYLAXIS		Trial and failure of both an anticonvulsant and a beta blocker (Step 1 agents) greater than or equal to three (3) months will be required before approval can be given for the step 2 agents. Concurrent use of Botox will not be approved. Nurtec will be limited to 16 tabs/30 days.	NURTEC
	STEP 1 AGENTS			
	beta blockers	divalproex topiramate		
	STEP 2 AGENTS		*Starting dose will be limited to 70mg **Approval for non-preferred agents requires trial and failure of a preferred agent along with the trial and failures described with Step 1 Agents' criteria above.	QULIPTA**
	ACUTE MIGRAINE TREATMENT			
	STEP 1 AGENTS		Trial and failure of two preferred agents will be required for approval of a non-preferred agent.	almotriptan ELYXB Sumatriptan-Naproxen Sodium TOSYMRA (use preferred agent) ZEMBRACE (use preferred agent) ZAVZPRET zolmitriptan
	frovatriptan naratriptan RELPA* sumatriptan rizatriptan		Rizatriptan will be limited to clients 6 years of age or older Quantity limits apply: naratriptan 1mg: 25 tabs/34 days naratriptan 2.5mg: 10 tabs/34 days RELPA* 20mg: 20 tabs/34 days RELPA* 40mg: 14 tabs/34 days rizatriptan 5mg: 27 doses/34 days rizatriptan 10mg: 14 doses/34 days sumatriptan vials: 2 vials/34 days sumatriptan nasal 20mg: 6 bottles/34 days; 5mg: 12 bottles/34 days sumatriptan 25mg: 41 tabs/34 days sumatriptan 50mg: 20 tabs/34 days sumatriptan 100mg: 10 tabs/34 days	
	STEP 2 AGENTS		Trial and failure of two triptan agents required for Step 2 Agent approval	
		NURTEC UBRELVY	Trial and failure of two preferred triptan agents AND Nurtec OR Ubrely will be required for approval of a non-preferred agent. Quantity limits apply: NURTEC 75mg: limited to 8 tabs/30 days	
MOVEMENT DISORDERS	VMAT 2 INHIBITORS		Quantity limits apply: AUSTEDO: limited to 4 tabs/day INGREZZA: limited to 4 tabs/day *Please refer to the Additional Therapeutic Criteria chart at www.wyicaid.org	INGREZZA (sprinkles)
	AUSTEDO/XR* INGREZZA* TETRABENAZINE			
MULTIPLE SCLEROSIS	MS AGENTS		Gilenya, Kesimpta, Lemtrada, Ocrevus, and Tysabri will be approved for highly active disease, please refer to the ATCC for additional information. Trial and failure of two preferred agents for at least 56 days (each from a separate class) will be required before approval can be given for a non-preferred agent. For Mavenclad, in addition to the above criteria, approval will be granted on a case-by-case basis.	AUBAGIO AVONEX BAFIERTAM BRIUMVI glatramer (BRAND IS PREFERRED) GLATOPA (use preferred agent) MAVENCLAD MAYZENT PLEGRIDY PONVORY TECFIDERA VUMERITY ZEPOSIA
	BETASERON COPAXONE 20MG/ML* dimethyl fumarate REBIF teriflunomide	GILENYA KESIMPTA** LEMTRADA OCREVUS TYSABRI		
NARCOLEPSY	STIMULANTS		Modafinil and Nuvigil: Client must be > 16 years of age. Client must have a diagnosis of narcolepsy, obstructive sleep apnea, shift work sleep disorder, Multiple Sclerosis (MS) Fatigue, or ADD/ADHD with a concurrent diagnosis of substance abuse. Diagnosis of MS will require a fatigue severity scale score of 5.0, a 60 day trial of amantadine AND discontinuation of medications that may contribute to drowsiness or fatigue. Please consult the Dose Limitation Chart for specific limits for diagnoses. Clients will not be allowed to take two or more agents in this class concurrently	SUNOSI WAKIX XYREM
	NON-STIMULANTS			
		modafinil NUVIGIL*		
NEUROPATHIC PAIN	GABAPENTIN		Clients will not be allowed to take gabapentin and pregabalin concurrently Prior authorizations for perioperative pain will be approved for gabapentin OR pregabalin for less than or equal to 14 day supplies	ZTLIDO
		gabapentin pregabalin		
	TOPICAL LIDOCAINE			
	Lidocaine Patches		Trial and failure of a tricyclic antidepressant greater than or equal to a 12 week supply AND trial and failure of gabapentin at a dose of 3600mg per day OR pregabalin for greater than or equal to a 12 week supply in the last 12 months will be required before approval can be given for a non-preferred agent.	imipramine (capsules) oxcarbazepine valproic acid
	ADDITIONAL AGENTS			
	amitriptyline desipramine imipramine (tablets) nortriptyline			
OBSTRUCTIVE SLEEP APNEA	GLP-1 Agonists		Client must have diagnosis of moderate to severe obstructive sleep apnea. Will be approved for obese adults with an AHI (Apnea-Hypopnea Index) of greater than 15 as evidenced by sleep study within the prior 12 months. Prior authorization will be required again at 6 months to show at least 5% weight loss. Prior authorization will be required again at 12 months to demonstrate improvement in obstructive sleep apnea.	
		ZEPBOUND		

**WYOMING MEDICAID
Preferred Drug List (PDL) June 8, 2026**

Please refer to the Additional Therapeutic Criteria Chart, [Dosage Limitation List](#) (red font indicates quantity/dose limits apply), and Wyoming Medicaid Provider Manual for additional criteria.

THERAPEUTIC CLASS	PREFERRED AGENTS	PREFERRED AGENTS REQUIRING CLINICAL CRITERIA	CLINICAL CRITERIA	NON-PREFERRED AGENTS GENERIC MANDATORY POLICY APPLIES <small>THIS LIST IS NOT ALL INCLUSIVE PLEASE CONTACT Opioids WITH ANY QUESTIONS</small>	
OPHTHALMICS	OP. -ANTI-ALLERGENICS		Trial and failure of a preferred agent greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent. Alomide and Alocril will be approved for pregnancy. Alomide will be approved for children under the age of 3.	bepotastine epinastine ZERVATE	
	ALREX azelastine BEPREVE* cromolyn 0.4%				
	OP. -ANTIBIOTICS- QUINOLONES			Trial and failure of a preferred agent greater than or equal to 5 days in the last 12 months will be required before approval can be given for a non-preferred agent.	gatifloxacin
	ciprofloxacin BESIVANCE gentamicin moxifloxacin 0.5% ofloxacin tobramycin				
	OP. -ANTI-INFLAMMATORY			Trial and failure of ALL preferred agents each greater than or equal to 5 day supply in the last 12 months will be required before approval can be given for a non- preferred agent.	ACULAR/LS/PF (use preferred agent) ACUVAIL bromfenac 0.9% BROMSITE DUREZOL ILEVRO INVELTYS LOTEMAX SM loteprednol 0.5% (BRAND IS PREFERRED) PROLENSA
	flurbiprofen diclofenac LOTEMAX* ketorolac NEVANAC				
	OP. -BETA-BLOCKERS			Trial and failure of three (3) preferred agents each greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non- preferred agent. *Betoptic S will be approved for those with heart and lung conditions.	BETIMOL BETOPIC S*
	betaxolol carteolol levobunolol timolol				
	OP. -CARBONIC ANHYDRASE INHIBITOR			Trial and failure of a preferred agent greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent.	brinzolamide (BRAND IS PREFERRED)
	AZOPT* dorzolamide				
	OP. -COMBO PRODUCTS				dorzolamide/timolol (BRAND IS PREFERRED)
	COMBIGAN* COSOPT ROCKLATAN SIMBRINZA				
	OP. -DRY EYE AGENTS			Trial and failure of the preferred agent greater than or equal to 12 weeks will be required before approval can be given for the non-preferred agent.	CEQUA cyclosporine (BRAND IS PREFERRED) EYSUVIS MIEBO RESTASIS MULTIDOSE (see preferred) TYRVAYA
	RESTASIS* XIIDRA				
OP. -PROSTAGLANDINS		Trial and failure of ALL preferred agents each greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non- preferred agent.	bimatoprost JYUZEH tafluprost		
latanoprost LUMIGAN TRAVATAN Z XALATAN ZIOPTAN					
OP. -RHO KINASE INHIBITOR					
RHOPRESSA					
OP. -SYMPATHOMIMETICS		Trial of a preferred agent greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent.	brimonidine 0.15% (BRAND IS PREFERRED)		
ALPHAGAN P 0.1% ALPHAGAN P 0.15%* brimonidine 0.2%					
OSTEOPOROSIS	BISPHOSPHONATES		Trial and failure of a preferred agent greater than or equal to 12 months will be required before approval can be given for a non-preferred agent. Fosamax liquid will be approved for clients that have difficulty swallowing. **Evinity will only be allowed for a maximum of 12 months of treatment, will not be allowed with any concurrent osteoporosis treatment, and will be limited to approved indication ***Will be limited to 2 years of use	EVENITY** FORTEO*** FOSAMAX-D TYMLOS***	
	alendronate ibandronate risedronate				
	NASAL CALCITONIN				
calcitonin-salmon					
OTIC	ANTIBIOTIC/STEROID COMBINATION		Trial and failure of a preferred agent greater than or equal to 14 day supply in the last 12 months will be required before approval can be given for a non-preferred agent. Oxytrol will be approved for clients that have an inability to swallow.	ciprofloxacin 0.2% (use preferred agent) CIPRO HC (use preferred agent) CORTISPORIN-TC (use preferred agent) FLUOCINOLONE ACET OIL 0.01% (use preferred agent)	
	ciprofloxacin/dexamethasone Neo/Poly/HC suspension/solution ofloxacin tobramycin/dexamethasone				
OVERACTIVE BLADDER	OVERACTIVE BLADDER AGENTS		Trial and failure of a preferred agent greater than or equal to 14 day supply in the last 12 months will be required before approval can be given for a non-preferred agent. Oxytrol will be approved for clients that have an inability to swallow.	darifenacin GEMTESA mirabegron (BRAND IS PREFERRED) OXYTROL DIS tolterodine/ER TOVIAZ trospium	
	MYRBETRIQ* oxybutynin /ER solifenacin				
PAIN	LONG-ACTING C-III's		Trial and failure of a preferred agent(s) greater than or equal to a 14 day supply in the last 12 months will be required before approval can be given for a non- preferred agent. C-III's and C-IV's that are not included on the PDL and are generally available without prior authorization Concurrent therapy with a benzodiazepine and a narcotic medication or with duplicate benzodiazepines is not covered by Wyoming Medicaid. A single medication will continue to be allowed to process unless another benzodiazepine (or narcotic) is billed to Wyoming Medicaid. Fentanyl: 37.5mcg, 1 strength at a time, 1 patch every 3 days Hydromorphone ER: 30mg/day Hysingla ER: 120mg/day Methadone: Limited to 3 tablets per day Morphine ER: 90mg/day Oxycontin: 60mg/day Oxymorphone: 40mg/day Clients will be limited to one long-acting narcotic at a time.	fentanyl patches hydrocodone ER hydromorphone ER HYSINGLA ER METHADONE morphine ER caasules (use preferred agents) oxymorphone ER OXYCONTIN	
	morphine ER tablets				

**WYOMING MEDICAID
Preferred Drug List (PDL) June 8, 2026**

Please refer to the Additional Therapeutic Criteria Chart, [Dosage Limitation List \(red font indicates quantity/dose limits apply\)](#), and Wyoming Medicaid Provider Manual for additional criteria.

THERAPEUTIC CLASS	PREFERRED AGENTS	PREFERRED AGENTS REQUIRING CLINICAL CRITERIA	CLINICAL CRITERIA	NON-PREFERRED AGENTS GENERIC MANDATORY POLICY APPLIES <small>THIS LIST IS NOT ALL-INCLUSIVE PLEASE CONTACT ODHSMR WITH ANY QUESTIONS</small>
PAIN continued	SHORT-ACTING C-Its		Trial and failure of three (3) preferred agents greater than or equal to a 6 day supply in the last 90 days will be required before approval can be given for a non-preferred agent. Concurrent therapy with a benzodiazepine and a narcotic medication or with duplicate benzodiazepines is not covered by Wyoming Medicaid. A single medication will continue to be allowed to process unless another benzodiazepine (or narcotic) is billed to Wyoming Medicaid. All short-acting narcotics, long-acting narcotics, OR combinations thereof, will be limited to a total dose of 90 MME per day. Clients will be limited to one short-acting narcotic at a time	levorphanol oxycodone ROXYBOND
	codeine sulfate hydrocodone/APAP hydrocodone/IBU hydromorphone meperidine morphine oxycodone oxycodone/APAP			
	C-III/C-IV AGENTS		Trial and failure of a preferred agent(s) greater than or equal to a 14 day supply in the last 12 months will be required before approval can be given for a non-preferred agent. Quantity and dosage limits apply (max 8 tabs/day). Concurrent therapy with a benzodiazepine and a narcotic medication or with duplicate benzodiazepines is not covered by Wyoming Medicaid. A single medication will continue to be allowed to process unless another benzodiazepine (or narcotic) is billed to Wyoming Medicaid.	BELBUCA tramadol/apap tramadol ER capsules/tablets
	BUTRANS* tramadol			
PARKINSON'S DISEASE	SHORT-ACTING AGENTS			
	amantadine benztropine tablets carbidopa/levodopa pramipexole ropinirole			
	LONG-ACTING AGENTS		**Non-preferred Parkinson's agents will require a 30 day trial and failure of 2 preferred medications including at least one short-acting agent and one long-acting agent *Neupro will be approved for clients with difficulty swallowing	APOKYN benztropine injectables GOCOVRI INBRIJA NEUPRO* ONGENTYS pramipexole ER XADAGO
	ropinirole ER RYTARY			
PHOSPHATE BINDERS	PHOSPHATE BINDERS		Prior authorization required for non-preferred agents.	AURYXIA lanthanum sevelamer VELPHORO
PROSTATE	5-ALPHA-REDUCTASE INHIBITORS		Trial and failure of a preferred agent greater than or equal to a 30 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	dutasteride dutasteride/tamsulosin (use separate agents)
	finasteride			
	ALPHA BLOCKERS		Trial and failure of a preferred agent greater than or equal to a 30 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	alfuzosin dutasteride/tamsulosin (use separate agents) silodosin
	doxazosin tamsulosin terazosin			
PULMONARY ANTIHYPERTENSIVES	5-ALPHA-REDUCTASE INHIBITORS		Prior authorization required. Client must have a diagnosis of pulmonary hypertension.	OPSYNVI
		ALYQ sildenafil suspension sildenafil (A/B rated generics)		
	ENDOTHELIN RECEPTOR ANTAGONISTS		Prior authorization required. Client must have a diagnosis of pulmonary hypertension.	bosentan (BRAND IS PREFERRED) OPSUMIT (use preferred agent) TRACLEER TABS FOR ORAL SUSP (use preferred agent) WINREVAIR
		LETAIRIS TRACLEER TABS*		
	GUANYLATE CYCLASE INHIBITORS		Prior authorization required.	ADEMPAS (use preferred agent)
	PROSTACYCLINE VASODILATORS		Prior authorization required. Client must have a diagnosis of pulmonary hypertension.	
		ORENTRAM		
	PROSTACYCLINE RECEPTOR AGONIST		Prior authorization required.	UPTRAVI (use preferred agent)
RESTLESS LEG SYNDROME	RESTLESS LEG SYNDROME		Client must have a diagnosis of Restless Leg Syndrome (RLS). Trial and failure of gabapentin greater than or equal to 60 days and a trial and failure of a dopamine agonist greater than or equal to 60 days in the last 12 months will be required before approval can be given for a non-preferred agent. *Neupro will be approved for clients with difficulty swallowing or for clients with a diagnosis of Parkinson's Disease. Clients will not be allowed to take gabapentin and pregabalin concurrently	HORIZANT NEUPRO*
	pramipexole ropinirole	gabapentin pregabalin		
SKELETAL MUSCLE RELAXANTS	MUSCLE RELAXANTS		Trial and failure of a preferred agent greater than or equal to a 14 day supply in the last 12 months will be required before approval can be given for a non-preferred agent. Cyclobenzaprine will require a prior authorization for clients concurrently taking a tricyclic antidepressant. Carisoprodol is limited to 84 tabs/365 days	carisoprodol chlorzoxazone cyclobenzaprine ER metaxalone methocarbamol orphenadrine tizanidine capsules (use preferred agent)
	baclofen (5, 10, 20mg tablets) cyclobenzaprine tizanidine tablets			
ULCERATIVE COLITIS	IMMUNOMODULATORS		Client must have diagnosis of UC prior to approval of a preferred agent. To receive a non-preferred agent, client must have a diagnosis of UC and a 56-day trial and failure of the preferred agent. * Refer to Additional Therapeutics Clinical Criteria Chart for more information	ENTYVIO* REMICADE SIMPONI SKYRIZI STELARA TREMIFYA XELJANZ/XR
		adalimumab-fkjp HADUMA HUMIRA RINVOQ		
UVEITIS	IMMUNOMODULATORS		Client must have diagnosis of non-infectious intermediate, posterior, or panuveitis	
		adalimumab-fkjp HADUMA HUMIRA		